RxDoctor Payments Data

Elysa Marco

Neurodevelopmental Disabilities · San Francisco, CANPI 1518032713

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $10,000 of the $10,037 with a category attached, or 99.6%. Sage Therapeutics, LLC accounts for 99.6% of it on its own, with 1 other manufacturer making up the rest.

$10,037in general payments, 2019–2025

Across 7 payments — averaging $1433.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sage Therapeutics, LLC$10K
  • Astellas Pharma US Inc$37
$651,250in research payments, 2019–2025

Across 47 payments — averaging $13,856 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Acadia Pharmaceuticals Inc$651K

What the payments were for

  • Consulting fees$10,000100%
  • Food & beverage$370%

General payments by program year

22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sage Therapeutics, LLC6$10,000
Astellas Pharma US Inc1$37

How this compares

$10,037 in reported general payments places this provider in the 75th percentile of 21 neurodevelopmental disabilities providers in California.

See all neurodevelopmental disabilities providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
ValtocoDiazepam12$9,939
Lamotrigine ErLamotrigine17$6,781
Propranolol Hcl14$811
Olanzapine16$741
Trazodone Hcl24$601
Buspirone Hcl18$430
Clonazepam13$6

Paid to pharmacies, not to this prescriber.

Other neurodevelopmental disabilities in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →